Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EL Bruton's tyrosine kinase (BTK) inhibitors
L01EL01 Ibrutinib
D10223 Ibrutinib (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Bruton Tyrosine Kinase Inhibitors
Ibrutinib
D10223 Ibrutinib (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D10223 Ibrutinib (JAN/USAN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG02022 BTK inhibitor
D10223 Ibrutinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
D10223 Ibrutinib
Drug classes [BR:br08332]
Antineoplastic
DG02022 BTK inhibitor
D10223 Ibrutinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Non-receptor tyrosine kinases
TEC family
BTK
D10223 Ibrutinib (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10223
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10223
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10223
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10223
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10223
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D10223